New Gout Drug Krystexxa Exceeds Target
There is increased hope for the roughly 3% of chronic, severe gout sufferers who do not respond to current gout medications. Within recent period III trials of the new gout medication Krystexxa, an impressive 42% of refractory gout patients achieved statistically significant reductions in uric acid levels, as well as sustained all of them for six months. This exceeeded the target amount set for the study by the drug's manufacturer, Savient Pharmaceuticals. In comparison, those gout patients in the trial that received a placebo saw no reduction in uric acid levels.
When you've seriously ill people who have no options, 40 percent will be pretty good," said Dr. Michael Becker from the University of Chicago," author of the newest study, which was published in the Journal of the American Medical Association. "Gout can be a sincere about and disabling disease."
Krystexxa (generic name plegloticase) has been FDA approved in 2010 based on earlier clinical trials. The newest gout medicine, which is administered by intravenous infusion, is derived from an animal hormone. The pegloticase mechanism of action is different than that of other gout drugs - it converts uric acid to a nontoxic byproduct that is easily excreted in the urine.
- High levels of uric acid are usually the cause of gout, an extremely painful form of arthritis.
- The excess acid crystallizes into filling device sharp deposits in the joints, usually at the base of the big toe.
- The uric acid can also form knobby, chalky mounds called tophi.
- Tophi can be reabsorbed back into the body if uric acid levels are reduced.
- Forty percent of the trial members with tophi skilled a resolution of one or more of the lumpy deposits.
Krystexxa Emerged Intravenously Over No Less Than Two Hours Every Two Weeks
The Food has warned that patients should be given a corticosteroid and antihistamine before infusions as a result of high risk of allergic reaction. Other common side effects of Krystexxa are gout flare ups (which occurred in 80% of the recent trial participants), nausea and vomiting, chest pain, constipation, nasal irritation and bruising at the injection site.
Investigational Gout Drugs Do Well in Clinical Trials Two major American drug companies are racing to get rival new gout medications to market. Both gout medicines take novel approaches to treating refractory gout - gout that hasn t already responded well to current treatment.Ardea Biosciences had...
How to Treat Gout Naturally
http://articles.mercola.com/sites/articles/archive/2010/01/19/Five-Steps-to-Overcoming-Gout-Naturally.aspx Natural health physician and Mercola.com founder ...
Krystexxa is not intended for use in the average gouty arthritis patient, most of which can be treated with more traditional gout medications such as Colcrys (generic colchicine) or Zyloprim (generic allopurinal). Currently, the new injectable gout drug costs about $5000 a month. It's hoped that gout patients who respond well to the treatment could at some point use cheaper gout drugs.
Armed with these impressive new results, Savient Pharmaceuticals intends to amp up advertising of its new gout drug in the US and other countries. Up to now, their advertising efforts have largely been aimed at rheumatologists, but they now plan to expand their own efforts to include primary care physicians. "This really today is the foundation for our launch of period 2 in to the primary care audience," said Savient Chief Executive Officer John Johnson.
Johnson says the pharmaceutical company "expects to see several velocity within sales" as a result of their increased target market. The company is said to be disappointed in the $1.4 thousand bucks in net sales the gout medicine generated in the first six months after receiving Food and drug administration approval.
Alex Ray Advocates for Affordable Access to Healthcare and Medication
She recommends Big Mountain Drugs as a reliable on the internet Canadian pharmacy from which to buy colchicine and allopurinol regarding gout. For more information about gout and gout medication, visit the online resource www.colchicine.ca.